Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BIXT NASDAQ:CVKD NYSEARCA:DBV NASDAQ:ENLV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIXTBioxytran$0.08+0.3%$0.09$0.06▼$0.23$7.02M1.94184,386 shs300 shsCVKDCadrenal Therapeutics$13.29+1.5%$12.07$7.06▼$22.90$27.23M0.9532,528 shs1,683 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AENLVEnlivex Therapeutics$1.03-0.5%$1.25$0.81▼$2.10$24.36M0.83258,479 shs32,533 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIXTBioxytran+2.34%+5.35%-1.62%-34.42%-9.12%CVKDCadrenal Therapeutics-2.02%+5.56%+17.49%-12.67%+77.51%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%ENLVEnlivex Therapeutics-0.96%-2.83%-27.97%+9.34%-14.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIXTBioxytran$0.08+0.3%$0.09$0.06▼$0.23$7.02M1.94184,386 shs300 shsCVKDCadrenal Therapeutics$13.29+1.5%$12.07$7.06▼$22.90$27.23M0.9532,528 shs1,683 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AENLVEnlivex Therapeutics$1.03-0.5%$1.25$0.81▼$2.10$24.36M0.83258,479 shs32,533 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIXTBioxytran+2.34%+5.35%-1.62%-34.42%-9.12%CVKDCadrenal Therapeutics-2.02%+5.56%+17.49%-12.67%+77.51%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%ENLVEnlivex Therapeutics-0.96%-2.83%-27.97%+9.34%-14.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIXTBioxytran 0.00N/AN/AN/ACVKDCadrenal Therapeutics 3.00Buy$32.00140.87% UpsideDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AENLVEnlivex Therapeutics 3.00Buy$10.00875.61% UpsideCurrent Analyst Ratings BreakdownLatest BIXT, CVKD, DBV, and ENLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/18/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/29/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/22/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIXTBioxytranN/AN/AN/AN/A($0.02) per shareN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIXTBioxytran-$2.37M-$0.03N/A∞N/AN/AN/A-1,577.96%N/ACVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)DBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AENLVEnlivex Therapeutics-$15.01M-$0.58N/AN/AN/AN/A-58.31%-50.32%N/ALatest BIXT, CVKD, DBV, and ENLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIXTBioxytranN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIXTBioxytranN/AN/AN/ACVKDCadrenal TherapeuticsN/A3.553.55DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AENLVEnlivex TherapeuticsN/A6.416.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIXTBioxytranN/ACVKDCadrenal Therapeutics7.92%DBVInvesco DB G10 Currency Harvest Fund85.24%ENLVEnlivex Therapeutics1.02%Insider OwnershipCompanyInsider OwnershipBIXTBioxytran70.00%CVKDCadrenal Therapeutics26.09%DBVInvesco DB G10 Currency Harvest FundN/AENLVEnlivex Therapeutics12.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIXTBioxytran288.99 million26.70 millionNot OptionableCVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableBIXT, CVKD, DBV, and ENLV HeadlinesRecent News About These CompaniesEnlivex Therapeutics announces issuance of Israeli patent for AllocetraSeptember 10 at 2:42 AM | msn.comEnlivex Secures Israeli Patent for Osteoarthritis TreatmentSeptember 9 at 8:51 AM | tipranks.comEnlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with OsteoarthritisSeptember 9 at 8:00 AM | globenewswire.comHC Wainwright Has Bullish Forecast for ENLV Q3 EarningsSeptember 6, 2025 | americanbankingnews.comQ1 Earnings Estimate for ENLV Issued By HC WainwrightSeptember 5, 2025 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Enlivex Therapeutics (NASDAQ:ENLV)September 4, 2025 | americanbankingnews.comEnlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Sell at Wall Street ZenAugust 31, 2025 | americanbankingnews.comEnlivex Reports Financial Results for Mid-2025August 29, 2025 | tipranks.comEnlivex stock soars after positive knee osteoarthritis trial dataAugust 18, 2025 | investing.comEnlivex Therapeutics announces topline data from Phase I/II trial of AllocetraAugust 18, 2025 | msn.comEnlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee OsteoarthritisAugust 18, 2025 | globenewswire.comEnlivex to Present Key Results from Osteoarthritis TrialAugust 14, 2025 | msn.comEnlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 WebinarAugust 14, 2025 | globenewswire.comEnlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline DataJuly 28, 2025 | globenewswire.comEnlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJune 13, 2025 | usatoday.comEnlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in BarcelonaJune 11, 2025 | nasdaq.comEnlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of RheumatologyJune 10, 2025 | globenewswire.comEnlivex Selected to Present at Israeli BioMed 2025 ConferenceMay 20, 2025 | globenewswire.comEnlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World CongressApril 23, 2025 | globenewswire.comEnlivex enrols all patients in Phase II stage of knee osteoarthritis trialApril 23, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIXT, CVKD, DBV, and ENLV Company DescriptionsBioxytran OTCMKTS:BIXT$0.08 +0.00 (+0.25%) As of 09:30 AM EasternBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.Cadrenal Therapeutics NASDAQ:CVKD$13.28 +0.20 (+1.49%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.Enlivex Therapeutics NASDAQ:ENLV$1.02 -0.01 (-0.49%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market The Quiet Before the Catalyst: Vertical Aerospace's Next Move Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
